Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMC-310911
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TMC-310911 (also known as ASC-09) is a novel investigational small molecule protease inhibitor structurally related to darunavir. It was originally developed for the treatment of HIV/AIDS and has demonstrated potent activity against wild-type and multi-protease inhibitor-resistant strains of HIV-1, making it potentially useful for both treatment-naive and experienced patients. The drug acts by inhibiting the HIV protease enzyme, thereby preventing the cleavage of viral Gag and Gag-Pol polyproteins, which results in immature, non-infectious viral particles and blocks viral replication. In addition to its primary indication in HIV infection, TMC-310911 has also been investigated as a potential therapy for COVID-19 due to its ability to inhibit viral proteases from other RNA viruses such as SARS-CoV-2. The drug was developed by Tibotec Pharmaceuticals (now part of Janssen R&D Ireland), but no recent development or approval has been reported[1][2][3][4][5].
- Other names
- TMC310911TMC-310911TMC 310911
02
Targets
PR (Progesterone receptor)Gag-Pol (HIV-1 gag-pol polyprotein)
Beyond the preview
Go deeper on TMC-310911.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMC-310911.